ClinicalTrials.Veeva

Menu
The trial is taking place at:
U

United Medical Research Institute | Inglewood, CA

Veeva-enabled site

RMP-A03 Ocular Suspension in Patients With Pterygium

S

Suzhou Raymon Pharmaceuticals Company

Status and phase

Active, not recruiting
Phase 2

Conditions

Pterygium

Treatments

Drug: RMP-A03 - Dose 1
Drug: RMP-A03 - Dose 2
Drug: RMP-A03 Placebo

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT05794204
RMP-A03-001

Details and patient eligibility

About

The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.

Full description

Following informed consent, patients with pterygium who meet all eligibility criteria will be randomized to an 84-day double-blinded study to measure the safety and efficacy of the study drug as compared to placebo.

Enrollment

75 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must be at least 18 years old
  • Diagnosis of pterygium with specified characteristics
  • BCVA of 20/200 or better
  • Willingness to attend all study visits and comply with the study procedures

Exclusion criteria

  • Presence of ocular disease
  • Double pterygium
  • History of ocular surgery
  • Presence of ocular trauma
  • Use of any ocular medication
  • Use of contact lens
  • Allergy to any of the components of study drug
  • Cannot properly administer study drug
  • Clinically significant systemic disease that may place the subject at risk or confound study results
  • Participation in an investigational study within 30 days prior to screening
  • Female participants who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control (WOCBP).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

75 participants in 3 patient groups, including a placebo group

Patients randomized to dose 1 study drug
Experimental group
Description:
Approximately 25 patients randomized to dose 1 of RMP-A03
Treatment:
Drug: RMP-A03 - Dose 1
Patients randomized to dose 2 of study drug
Experimental group
Description:
Approximately 25 patients randomized to dose 2 of RMP-A03
Treatment:
Drug: RMP-A03 - Dose 2
Patients randomized to placebo
Placebo Comparator group
Description:
Approximately 25 patients randomized to placebo.
Treatment:
Drug: RMP-A03 Placebo

Trial contacts and locations

6

Loading...

Central trial contact

Ashlea Beck

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems